Medvient, Inc. — SEC Form D Filing

Medvient, Inc. filed an SEC Form D on July 10, 2026, reporting $90K raised in Healthcare Technology.

Form D filing details

Filing
SEC Form D
Filing date
July 10, 2026
Amount reported
$90K
Round stage
Seed
Industry
Healthcare Technology
Website
https://medvient.co/

What the company does

Securities: Debt. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Medical practices lose significant revenue due to preventable claim denials, undisputepensed out-of-network claims, and other hidden inefficiencies in the billing process. This complex billing system makes it difficult for practices to recover money they have already earned.

Solution

Medvient offers a suite of products, including Medvient Recon, to help practices identify revenue leakage, analyze denials, and provide a 30-day recovery plan. Coming soon, Medvient Defense will address complex denial and payer disputes, and Medvient Clinical will assist with documentation and claim creation.

Why now

Medvient is being started at this moment due to the increasing complexity and volume of healthcare insurance audits, creating a critical need for technological solutions like IDR Defense Recon to accurately identify and recover lost revenue for companies.

Verdict

Investors backed Medvient for its promise of concrete revenue recovery in a known pain point, not for innovative technological breakthroughs. The implicit bet was on the immediate, tangible ROI for practice managers navigating complex billing, providing a clear value proposition. Upside was limited by the reliance on existing data structures and the potential for larger RCM players to integrate similar recovery modules, effectively commoditizing the niche rather than building a new category.

Source: SEC EDGAR Form D filing